Takeaway: Maybe mRNA technology, like amyloid research is nothing more than a stranded asset in search of a vehicle to monetarization; MRNA, PFE, BNTX

As we try and size the true TAM for mRNA technology for PFE and MRNA, we have found a few people to help this Art History major who could not make it through biochemistry. Last week, we spent time with Dr. Tracy Beth Hoeg to learn about her research on adverse events, especially among young men. This week we had the pleasure of meeting and learning from Dr. Aditi Bhargava of the University of California, San Francisco. Dr. Bhargava's background is in molecular biology but she has done extensive work on its intersection with physiology. Link to her bio and publications here. 


0:00 - 3:56 Introduction and Background

3:56 - 10:46 What is mRNA and How Does the Technology Work? (Microbiology 101)

10:47 - 20:01 Making mRNA Stable and the Cost of Doing So; Limited Research on Durability of Modified mRNA and Dosage Outside the Lab

20:01 - 26:17 Implication of Incomplete Modifications and Assumptions of Clearing Especially at Scale; MRNA's Failed Trial on H1N1; Repurposing a Stranded Asset

26:17 -  34:54 Mechanism for Cardiac Response (myo/pericarditis); Why Not Other Organs and a Really Great Rubber Band Analogy; Explaining Long COVIDand Unintended Consequences

34:54 -  48:36  The Aspirational Goals of MRNA and PFE for mRNA Technology and the Limitations of Technology; Alzheimer's, the Amyloid Debate and Aduhelm; False Hope and Malaria

48:36 - 56:05 Necessary and Missing Information Under the EUA; The Limits of Vaccines; Romance of Medicine